Overview: Ristocetin Cofactor TestIntroduction: The Ristocetin Cofactor Test measures ristocetin cofactor activity to diagnose von Willebrand disease, causing bleeding. Aligned with 2023 ASH guidelines, it uses coagulation assays for high specificity, supporting coagulation screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in coagulation for patients with suspected von Willebrand disease.
Other Names: Ristocetin Cofactor Assay, vWF Activity Test.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic accuracy.
Historical Milestone: Ristocetin cofactor testing began in the 1970s with von Willebrand disease research. Assay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures ristocetin cofactor activity to diagnose von Willebrand disease, guides treatment, and evaluates patients with bleeding.
Test Parameters: 1. Ristocetin Cofactor Activity
Pretest Condition: No fasting required. Collect plasma. Report history of bleeding or coagulation symptoms.
Specimen: Plasma (NaCit, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document bleeding, bruising, or family history of von Willebrand disease. Include current medications, especially antiplatelet drugs.
Consent: Written consent required, detailing the tests purpose, von Willebrand disease implications, and risks of sample collection.
Procedural Considerations: Uses aggregometry to measure ristocetin cofactor activity. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for von Willebrand disease diagnosis.
Factors Affecting Result Accuracy: Improper sample storage or anticoagulation therapy can affect results. Medications may alter activity levels.
Clinical Significance: Low ristocetin cofactor activity confirms von Willebrand disease, guiding DDAVP or factor replacement therapy. Normal levels may require vWF antigen testing.
Specialist Consultation: Consult a hematologist for result interpretation and treatment planning.
Additional Supporting Tests: vWF antigen, factor VIII, or platelet function tests to confirm von Willebrand disease diagnosis.
Test Limitations: Non-specific for certain bleeding disorders; clinical correlation is needed. Sample quality affects sensitivity.
References: ASH von Willebrand Disease Guidelines, 2023; Blood, Nichols WL, 2022.
